Distinguished in Fanconi Anemia

Dr. Jason Gotlib

Hematology
Stanford University
875 Blake Wilbur Dr, 
Palo Alto, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Fanconi Anemia
Stanford University
875 Blake Wilbur Dr, 
Palo Alto, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jason Gotlib is a Hematologist in Palo Alto, California. Dr. Gotlib is rated as a Distinguished provider by MediFind in the treatment of Fanconi Anemia. His top areas of expertise are Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Myelofibrosis, Bone Marrow Aspiration, and Tissue Biopsy.

His clinical research consists of co-authoring 244 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in CA
Hospital Affiliations
Stanford Health Care Tri-Valley
Community Hospital Of The Monterey Peninsula
Stanford Health Care
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Stanford University
875 Blake Wilbur Dr, Palo Alto, CA 94304
Other Locations
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
Enrollment Status: Recruiting
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Phase: Phase 2
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: Tagraxofusp
Study Phase: Phase 1/Phase 2
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 1
Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R
Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R
Enrollment Status: Completed
Publish Date: November 16, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)
A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)
Enrollment Status: Completed
Publish Date: January 29, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Ibrutinib in Advanced Systemic Mastocytosis
A Phase 2 Study of Ibrutinib in Advanced Systemic Mastocytosis
Enrollment Status: Terminated
Publish Date: September 20, 2018
Intervention Type: Drug
Study Phase: Phase 2
Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies
Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies
Enrollment Status: Completed
Publish Date: May 31, 2018
Intervention Type: Procedure
A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia
A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: May 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

244 Total Publications

Introduction to a How I Treat series on chronic myeloid leukemia.
Introduction to a How I Treat series on chronic myeloid leukemia.
Journal: Blood
Published: November 13, 2025
Similar Doctors
Advanced in Fanconi Anemia
Dr. Kenneth Weinberg
Hematology | Oncology
Advanced in Fanconi Anemia
Dr. Kenneth Weinberg
Hematology | Oncology

Lucile Packard Children's Hospital Stanford

725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
650-497-8953
Languages Spoken:
English
See accepted insurances

Kenneth Weinberg is a Hematologist and an Oncologist in Palo Alto, California. Dr. Weinberg is rated as an Advanced provider by MediFind in the treatment of Fanconi Anemia. His top areas of expertise are Fanconi Anemia, Congenital Aplastic Anemia, Aplastic Anemia, Anemia, and Bone Marrow Transplant.

Advanced in Fanconi Anemia
Dr. Bertil Glader
Hematology
Advanced in Fanconi Anemia
Dr. Bertil Glader
Hematology

Lucile Packard Children's Hospital Stanford

725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
650-497-8953
Languages Spoken:
English
See accepted insurances

Bertil Glader is a Hematologist in Palo Alto, California. Dr. Glader is rated as an Elite provider by MediFind in the treatment of Fanconi Anemia. His top areas of expertise are Aase Syndrome, Pyruvate Kinase Deficiency, Pure Red Cell Aplasia, Hemolytic Anemia, and Splenectomy.

Advanced in Fanconi Anemia
Dr. Robert Diep
Hematology
Advanced in Fanconi Anemia
Dr. Robert Diep
Hematology

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (0.1 miles away)
650-498-6000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Diep is a Hematologist in Palo Alto, California. Dr. Diep is rated as an Advanced provider by MediFind in the treatment of Fanconi Anemia. His top areas of expertise are Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Idiopathic Pulmonary Hemosiderosis, and Hemosiderosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gotlib's expertise for a condition
ConditionClose
View All 10 Elite Conditions
View All 12 Distinguished Conditions
View All 20 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile